Here is the design of a clinical trial:

Official Title: COLO-DETECT: A Randomised Controlled Trial of Lesion Detection at Colonoscopy Using the GI Genius Artificial Intelligence Platform

Included conditions:
- Colonic Polyp
- Colorectal Polyp
- Colorectal Adenoma
- Colorectal Adenomatous Polyp
- Colorectal SSA
- Sessile Serrated Adenoma
- Sessile Colonic Polyp

Study Armgroups:
- {'label': 'GI Genius-assisted colonoscopy (GGC)', 'type': 'EXPERIMENTAL', 'description': 'In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.', 'interventionNames': ['Device: GI Genius-assisted diagnostic colonoscopy']}
- {'label': 'Standard Colonoscopy (SC)', 'type': 'ACTIVE_COMPARATOR', 'description': 'In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.', 'interventionNames': ['Diagnostic Test: Diagnostic Colonoscopy']}

Interventions:
- {'type': 'DEVICE', 'name': 'GI Genius-assisted diagnostic colonoscopy', 'description': 'Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.', 'armGroupLabels': ['GI Genius-assisted colonoscopy (GGC)']}
- {'type': 'DIAGNOSTIC_TEST', 'name': 'Diagnostic Colonoscopy', 'description': 'Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.', 'armGroupLabels': ['Standard Colonoscopy (SC)']}

Primary Outcomes:
- {'measure': 'Number of adenomas per participant detected at colonoscopy as indicated by the Mean Number of Adenomas per Procedure (MAP)', 'description': 'The number of adenomas identified during each colonoscopy will be summed and divided by the total number of colonoscopies performed. MAP is usually expressed as a number to one decimal place (e.g. 1.2).', 'timeFrame': 'The number of adenomas detected in each procedure will be counted at 14 days post-procedure'}

Please estimate the sample size based on the assumption: 
90% power, two-sided test for difference in proportions, alpha value of 0.05, 10% attrition rate.
Sample size
        The primary outcome for COLOâDETECT is the difference in MAP between GGC and SC (for which a clinically meaningful mean difference has been considered to be 0.50 for screening patients and 0.30 for symptomatic patients) (based on communications between the senior author, the clinicians involved in the trial and taking opinion from other experts). Due to the importance of ADR in detection studies and its historical widespread use it is important that this study is also powered to demonstrate a difference in ADR.
        Exploratoryâand, importantly, separateâsample size calculations for MAP and ADR indicate that a larger sample would be required to detect a significant difference in ADR than in MAP; COLOâDETECT has therefore been powered to detect a clinically meaningful and statistically significant difference in ADR, which exceeds that required to detect such a difference in MAP. This represents a difference of 7% in ADR (with a clinically meaningful difference deemed to be 10% for screening patients and 5% for symptomatic patients). Assuming a mixed sample of 40% screening (BCSP) patients and 60% symptomatic patients, with a baseline ADR of 27.6% across the sample (by aggregating BCSP and nonâBCSP data), a superiority design including 2032 participants will be required to provide 90% power for a twoâsided test for difference in proportions with an alpha value of 0.05. Allowing for 10% attrition due to incomplete colonoscopies, the target sample size will be 1828 participants having a complete colonoscopy. This sample size will more than enable detection of a pooled difference of 0.18 mean difference in MAP.